Press releases
Daiichi Sankyo Records Valuation Loss, Goodwill Write-down, on Investment in Ranbaxy Laboratories view full story
 
FDA Cardio Renal Advisory Committee to Review Daiichi Sankyo, Lilly Drug Prasugrel view full story
 
Prasugrel Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP) view full story
 
Daiichi Sankyo, Inc. Awarded Prestigious NCQA Certification for National Under Pressure™ Hypertension Management Program view full story
 
New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients with Non-Valvular Atrial Fibrillation view full story
 
Daiichi Sankyo Initiates Phase III Trial of its Investigational Factor Xa Inhibitor, DU-176b, in Patients with Atrial Fibrillation view full story
 
Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients with Heterozygous Familial Hypercholesterolemia view full story
 
ArQule and Daiichi Sankyo Enter into Strategic R&D Partnership to Progress Novel Compounds to Target Cancer view full story
 
Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death view full story
 
Daiichi Sankyo and Lilly Respond to Speculation On Status of Prasugrel New Drug Application view full story
 
FDA Continues to Review Prasugrel New Drug Application view full story
 
Daiichi Sankyo, Inc. Files Supplemental New Drug Application for AZOR® as Initial Therapy for High Blood Pressure view full story
 
New Crossover Study Shows Prasugrel Significantly Reduced Platelet Aggregation in Patients with Acute Coronary Syndromes Compared with Clopidogrel at High Doses view full story
 
Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel view full story
 
Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b view full story
 
Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel view full story
 
Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events view full story
 
FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel view full story
 
National Under Pressure™ Hypertension Disease Management Program Now Specifically Tailored For African Americans view full story
 
Nuevo Estudio Muestra que el Benicar® (Olmesartan Medoxomil) Revierte los Daños a Vasos Sanguíneos Independientemente de la Disminución de la Presión Arterial view full story
 
New Study Shows Benicar®(olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering view full story
 
Ranbaxy to bring in Daiichi Sankyo as Majority Partner. Strategic Combination creates Innovator and Generic Pharma Powerhouse view full story
 
New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder view full story
 
Welchol™ Lowered A1C by A Mean 1% or Greater when Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47% of Patients Evaluated view full story
 
Daiichi Sankyo Announces Acquisition of Biotech Firm U3 Pharma AG view full story
 
Data from Pooled Analyses Demonstrate Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes view full story
 
AZOR™ Reduces Blood Pressure in Difficult to Treat Special Populations view full story
 
New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR® and BENICAR HCT® view full story
 
Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-promotion Agreement view full story
 
Welchol® Added to the American College of Endocrinology/American Association of Clinical Endocrinologists. “Road Maps to Achieve Glycemic Control in Patients with Type 2 Diabetes Mellitus” view full story
 
Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel view full story
 
FDA grants priority review for Daiichi Sankyo, Lilly drug, prasugrel view full story
 
Daiichi Sankyo, Lilly Submit Marketing Authorization Application for Investigational Oral Antiplatelet Drug, Prasugrel, to European Medicines Agency view full story
 
Welchol™ (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes view full story
 
Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration view full story
 
State Highlights Daiichi Sankyo During Life Sciences Week view full story
 
In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack view full story
 
Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel view full story
 
Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies view full story
 
Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR™ view full story
 
Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize.The company discusses increasing New Jersey life sciences jobs with Congressman Rodney Frelinghuysen view full story
 
AZOR™ Receives FDA Approval for Treatment of High Blood Pressure. Powerful New Combination Treatment Option Reduces Mean Systolic Blood Pressure Up to 30 Points view full story
 
New Survey Reveals Many Adults with High Cholesterol Fail to Take Necessary Steps to Improve Their Condition view full story
 
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR view full story
 
New study demonstrates Colesevelam HCI lowers both A1C and LDL cholesterol in patients with uncontrolled Type 2 diabetes mellitus on Metformin-based regimen view full story
 
Colesevelam HCI Combined With Metformin or with Sulfonylurea-based Therapy Significantly Lowers Blood Glucose (A1C) in Patients with Type 2 Diabetes view full story
 
Benicar HCT® Reductions in seated systolic blood pressure for Stage 2 patients compared with Amlodipine benazepril view full story
 
Amlodipine and Olmesartan Study Results Released;
Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007) view full story
 
Enrollment Completed in Pivotal Phase III Study Comparing Prasugrel to
Clopidogrel in Patients with Acute Coronary Syndrome view full story
 
Daiichi Sankyo, Inc. Announces Filing of Supplemental New Drug Application for
WelChol in the Treatment of Type 2 Diabetes Mellitus view full story
 
Daiichi Sankyo, Inc. Announces Filing of New Drug Application for
Amlodipine Besylate/ Olmesartan Medoxomil Combination for the Treatment of
Hypertension view full story
 
New Study Shows Prasugrel Achieves Faster Onset and Higher Levels of
Platelet Inhibition than Clopidogrel at Approved or Higher Doses view full story
 
Sankyo Pharma Inc., Daiichi Pharmaceutical Corporation, Daiichi Medical Research
Complete U.S. Integration view full story
Trademarks not owned by Daiichi Sankyo, Inc. are the property of their respective owners.